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Abbreviation List: AHRF: Acute Hypoxemic Respiratory failure; ARDS:  Acute Respiratory 
Distress Syndrome; ECMO: Extracorporeal membrane oxygenation; HFOV: high 
frequency oscillatory ventilation; iVD: inhaled vasodilators; ICU: Intensive Care Units; 
NMBA: neuromuscular blocking agent; PP: prone positioning; P/F ratio: PaO2/FiO2; PEEP: 
Positive End Expiratory Pressure  
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Abstract 
Background: Adjunctive strategies are an important part of the management of acute 
respiratory distress syndrome (ARDS). However, their application in clinical practice 
remains inconsistent. 
Research Question:  We wished to determine the frequency and patterns of use of 
adjunctive strategies in patients with moderate-severe ARDS (P/F ratio < 150) enrolled 
into the Large observational study to UNderstand the Global impact of Severe Acute 
respiratory FailurE (LUNG SAFE) study. 
Study Design and Methods: The LUNG SAFE study was an international, multicenter, 
prospective cohort study of patients with severe respiratory failure, conducted in 2014 
in 459 ICUs from 50 countries. The primary objective of this substudy was to determine 
the frequency of use of widely available (neuromuscular blockade, prone position) 
adjuncts versus adjuncts requiring specialized equipment (ECMO, Inhaled vasodilators, 
HFOV) in patients in the first 48 hours of moderate-severe ARDS (P/F ratio < 150). 
Results: Of 1,151 invasively ventilated patients with moderate-severe ARDS, 818 pts 
(71%) received no adjunct within 48h of ARDS onset. Of 335 (29%) that received 
adjunctive strategies, 248 (75%) received a single strategy, and 85 (26%) receiving more 
than one adjunct. Of ARDS non-survivors, 67% did not receive any adjunctive strategy in 
the first 48 hours. Most patients (63%) receiving specialized adjuncts did not receive 
prone positioning or neuromuscular blockade. Patients that received adjuncts were 
more likely to have their ARDS recognized, be younger and sicker, have pneumonia, and 
be more difficult to ventilate, and be in a European high income country than those that 
did not receive adjuncts. 
Interpretation: Three in ten patients with moderate-severe ARDS, and only one third of 
non-survivors, received adjunctive strategies over the first 48 hours of ARDS. A more 
consistent and evidence driven approach to adjunct use may reduce costs and improve 
outcomes in patients with moderate-severe ARDS.  
Trial Registration: ClinicalTrials.gov NCT02010073 
5 
 
6 
 
Introduction  
Adjunctive therapies constitute an important part of the management of early 
moderate to severe acute respiratory distress syndrome (ARDS). However their 
application in clinical practice appears variable and inconsistent 1,2. Underlying reasons 
for this heterogeneity may include the availability of adjuncts, which varies from widely 
available adjuncts such as prone positioning (PP) and neuromuscular blockade (NMB) to 
those which require more specialized equipment and expertise, including extracorporeal 
membrane oxygenation (ECMO), inhaled vasodilators (iVD) and high frequency 
ventilation (HFOV). A second issue may be the variable level of scientific evidence that 
underpins the use of different adjunctive strategies, which varies from robust evidence 
for PP 3, to potential benefits  for NMB 4 and for ECMO 5,6, to little evidence for inhaled 
vasodilators 7 to potential for harm with HFOV 8,9.  
 
The Large observational study to UNderstand the Global impact of Severe Acute 
respiratory FailurE (LUNG SAFE) study was undertaken in 459 Intensive Care Units (ICUs) 
in 50 countries across 5 continents 10. One key finding was that the use of contemporary 
evidence-based ventilatory strategies and adjunctive strategies was lower than 
expected 10. The primary objective of this secondary study was to determine the 
frequency of use of adjunctive strategies in patients in the first 48 hours of moderate-
severe ARDS (P/F ratio < 150) in the LUNG SAFE Cohort. Key secondary objectives 
included understanding patterns of use of adjuncts, the approach to using adjunctive 
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strategies, the relationship between adjunct use and their supporting evidence base, 
and factors associated with the use of adjunctive strategies in early ARDS. 
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Methods  
Study Design 
The detailed methods and protocol have been published elsewhere 10. In brief, LUNG 
SAFE was an international, multicenter, prospective cohort study, which recruited 3,033 
patients with ARDS from 459 Intensive Care Units (ICUs) in 50 countries across 5 
continents 10. The study, funded by the European Society of Intensive Care Medicine 
(ESICM), was endorsed by multiple national societies/networks (Appendix 1). All 
participating ICUs obtained ethics committee approval, and either patient consent or 
ethics committee waiver of consent. National coordinators and site investigators 
(Appendix 1) were responsible for obtaining ethics committee approval and for ensuring 
data integrity and validity.  
 
Patient Selection, Study Design and data collection 
 Inclusion criteria for the present study included: development of ARDS within 48 hours 
of the diagnosis of Acute Hypoxemic Respiratory failure (AHRF); a P/F ratio <150 within 
48 h of ARDS diagnosis; in patients undergoing invasive mechanical ventilation.  
Exclusion criteria included patients transferred from an external ICU and unknown 
admission source, as these patients may have received adjunctive strategies before 
inclusion into the study.  
Adjunctive therapies were defined as the use of prone positioning (PP), continuous 
neuromuscular blocking agents (NMBA), inhaled vasodilators, extracorporeal membrane 
oxygenation (ECMO), and high frequency oscillatory ventilation (HFOV). We did not 
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include recruitment maneuvers (RM) as LUNG SAFE data did not collect information on 
the number and type of recruitment maneuvers used. We divided the adjunctive 
strategies into adjuncts that were widely available (PP, NMBA) versus adjuncts that 
required specialized equipment (inhaled vasodilators, ECMO, HFOV). We examined use 
of adjuncts in the first 48 hours of ARDS, because this is where the evidence base for 
adjunct use exists.  
We also studied the variability and patterns of use of the adjunctive therapies in 
different geo-economic regions enrolling in the LUNG SAFE cohort. The 2016 World 
Bank countries classification was used to define three major geo-economic groupings: 
high-income countries in Europe, high-income countries in the rest of the world, and 
middle-income countries 11.  
 
Statistical Analysis 
Continuous variables were described by medians (interquartile ranges), and compared 
using unpaired Student’s t-test or Mann-Whitney U test, and one-way analysis of 
variance (ANOVA) or the Kruskal-Wallis H test, as appropriate. Bonferroni’s correction 
was used for multiple comparison. Proportions were used for categorical variables, and 
compared using χ2 or Fisher’s exact test. 95% Confidence Interval was reported for 
estimated proportions of patients who were treated with different patterns of 
adjunctive measures. We explored the presence of variables that could be associated 
with the use of adjunctive therapies by a univariate logistic regression analysis. Variables 
with a p-value<0.20 were included into a multivariable logistic regression model using a 
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stepwise selection approach. Statistical significance was considered with a p-value<0.05 
(two-tailed). Statistical analyses and graphs were performed using STATA-14/MP 
(StataCorp LP, College Station, TX, USA) and GraphPad Prism 7a (GraphPad Software, 
San Diego, CA, USA), respectively. 
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Results 
2,129 patients developed ARDS within 48 hours of AHRF onset, and received invasive 
MV, of whom 1,146 (54%) had moderate-severe ARDS (i.e. P/F ratio < 150) within the 
first 48 hours of ARDS.   
 
Frequency of adjunctive strategy use 
Adjuncts were used in the first 48 hours in 335 (29%) of patients with moderate-severe 
ARDS [Figure 1]. Of patients with ARDS that did not survive, 33% received an adjunct. Of 
these patients, 252 (75%) received a single adjunct, while 83 (25%) received two or 
more adjuncts [Figure 1]. Adjunct use at any time over the 28 day period following 
development of ARDS increased somewhat, with 37% of patients receiving an adjunct. 
Neuromuscular blockade was used in less than one third of patients (29%), prone 
positioning and inhaled vasodilators in 1 out of 10 patients and HFOV and ECMO in less 
than 2% of patients [Supplemental Table 1]. 
Patients receiving an adjunctive strategy were younger, and were more likely to have 
their ARDS recognized on day 1, be a medical admission, and have pneumonia [Table 1, 
Supplemental Tables 2-4]. Patients receiving adjuncts had more severe ARDS (i.e. lower 
P/F ratios), and were more difficult to ventilate (lower tidal volumes, higher PEEP, 
higher peak and plateau airway pressures) compared to patients treated only with 
conventional therapy [Table 1]. Furthermore, patients receiving adjunctive strategies 
had fewer nurses and more physicians per ICU bed in ICU [Table 1]. 
 
Widely available versus specialized adjuncts 
Of patients that received adjunctive strategies, the majority (n=249/335, 70%) received 
1 or more widely available adjuncts, while 30% received at least 1 specialized adjunct. 
Patients receiving specialized adjuncts were not different from patients receiving solely 
widely available adjuncts, apart from having a lower percentage of pulmonary risk 
factors, lower pH, more post-elective surgery [Table 1, Supplemental Tables 2-4]. Of 
interest, ARDS severity and ventilator settings were not different in patients that 
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received widely available adjuncts alone compared to those that received specialized 
adjuncts [Table 1, Supplemental Tables 2-4]. 
 
Patterns of adjunctive measure use 
Neuromuscular blocking agent (NMBA) infusion was the most frequently (255 patients, 
22%) used adjunct. It was used as a sole adjunct in 177 (69%) of these patients [Table 2].  
PP was the second most frequently used adjunct, used in 79 patients (7%), of whom 57 
(72%) received concomitant NMBA infusions. Inhaled vasodilator therapy was 
administered to 74 (6%) patients.  ECMO was initiated in 11 patients within the first 48 
hours, 5 (46%) of whom did not receive any other adjunctive therapies. HFOV was rarely 
used (0.5%) in this population. In patients that received multiple adjunctive therapies, 
there was significant variability in the combinations of adjuncts used. NMBA infusion 
and PP was the most frequent combination used [Table 2]. There was no difference in 
the frequency or pattern of adjunct use in surviving versus non-surviving patients over 
the first 48 hours of ARDS [Figure 2].  
There was no clear pattern of use for adjunctive strategies. Most patients receiving 
ECMO (6 of 11, 55%) and inhaled vasodilators (47 of 74, 64%) did not receive a more 
widely available adjunct strategy. Only 7 of 91 patients (8%) receiving specialized 
interventions received PP [Table 2]. 
 
Geo-economic variability in adjunct use 
European high income countries had the highest utilization of adjunctive strategies. The 
use of both NMBA and PP was significantly higher in European ICU’s when compared to 
the other geo-economic areas. Prone positioning was used less often in high income 
non- European countries. Use of other high resource intensive therapies were not 
different across different geo-economic areas [Table 3]. 
 
Factors associated with adjunct use  
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The use of adjuncts was independently associated with younger age and more severe 
ARDS (lower P/F ratio). These patients received lower tidal volumes, higher levels of 
PEEP, and had higher peak inspiratory pressures. Early clinician recognition of ARDS, a 
higher physician to bed ratio and a lower nurse to bed ratio were associated with early 
adjunct use. Geo-economic location was important, with adjunct use associated with 
high income European countries [Table 4]. 
 
Outcomes in patients receiving adjunctive strategies 
Crude ICU – but not hospital - mortality was greater in patients that received adjunctive 
strategies [Supplemental Table 5]. However, patients receiving adjunctive strategies 
had more severe ARDS, and were more difficult to ventilate [Supplemental Table 6]. 
There was no independent association between adjunct use and outcome in 
multivariate analyses [Supplemental Table 6]. 
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Discussion 
One-third of patients with moderate-severe ARDS received adjunctive strategies over 
the first 48 hours of ARDS in this study. Patients that received adjuncts were more likely 
to have their ARDS recognized, be younger and sicker, have pneumonia, and be more 
difficult to ventilate than those that did not receive adjuncts. They were more likely to 
receive treatment in a European high income country. There was no clear pattern in 
regard to the use of adjuncts in terms of their supporting evidence base or their 
resource requirements. Most patients receiving more specialized and expensive 
adjuncts did not also receive the more widely available adjuncts. ARDS severity did not 
appear to play a key role. In contrast geographical factors did appear important with 
markedly greater adjunct use in Europe. 
 
Frequency of adjunctive strategy use: A key finding of the study is the under use of 
adjuncts in patients with moderate-severe ARDS, which is of significant concern. Most 
patients with moderate-severe ARDS that died in ICU did not receive any adjunct in the 
first 48 hours, or at any time up to 28 days after developing ARDS. This low frequency of 
adjunct use is of concern.  
 
Patterns of adjunctive measure use: Illness severity appeared to play a role in the 
decision to use adjuncts, with factors related to ARDS severity and difficulty in 
ventilatory management both associated with adjunct use. The factors underlying the 
specific type of adjunct used were unclear. Most patients receiving specialized adjuncts 
did not also receive a more widely available adjunct. ARDS severity and mechanical 
ventilation indices were largely similar between patients receiving widely available 
versus specialized adjuncts.  
We did not find evidence for a sequential approach to use of adjunctive 
strategies, commencing with more widely available adjunctive strategies and 
progressing to more specialized and expensive adjuncts in patients that remain severely 
hypoxaemic. This approach has been used effectively in EOLIA, a recent large scale 
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clinical trial of ECMO 6, where 92 % of the patients received neuromuscular blocking 
agents, while 56% underwent PP before they were considered for extracorporeal 
support 6. Similarly in the ACURASYS trial of NM blockade, 45% of the patients received 
other adjunctive therapies (PP, Inhaled vasodilators or a combination) during the course 
of their ICU stay 4. In the PROSEVA trial 87% of the patients that underwent PP also 
received neuromuscular blocking agents, while 13 % also received inhaled vasodilators 3. 
Our findings support the proposal from Bein et al. for the use of protocols to guide the 
sequential application of adjunctive strategies based on the severity of hypoxemia 12.    
 
Factors influencing Adjunct Use: Understanding the barriers to the use of adjunctive 
strategies in patients with moderate-severe ARDS is an important step towards 
addressing this issue. The strength of the evidence base supporting the use of adjunctive 
strategies does not appear to be an important factor. Prone positioning has been clearly 
demonstrated to improve patient outcome 3, and is recommended in evidence-based 
guidelines for the management of ARDS 13. Despite this, only 7% of eligible patients 
received prone positioning, which is comparable to the frequency of inhaled vasodilator 
therapy use, an adjunct with a scant supporting evidence base. Prone positioning was 
rarely used in patients that received other, more specialized and costly adjunctive 
strategies such as ECMO. This confirms and extends the prior findings of Li and 
colleagues who found that most patients enrolled in older studies of ECMO did not first 
have a trial of PP 14, although this was improved in the more recent EOLIA study 6.  
ARDS remains an under-recognized condition 15, and this appears to have 
important implications for the management of these patients. Early recognition of ARDS 
by clinicians was independently associated with the use of adjunctive strategies. These 
findings are similar to a recent multicentre prospective study by Duan et al that showed 
that recognition of ARDS is associated with a higher use of adjunctive therapies 16.  
Geo-economic factors also appeared to play an important role, with patients in 
European high income countries more likely to receive adjunctive strategies, 
independent of other important covariates such as ARDS severity. Patients in high 
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income countries outside Europe were less likely to receive adjuncts, suggesting that 
resource constraints may not be the key issue. The evidence base for both 
neuromuscular blockade and prone positioning was developed largely in Europe 3,4. As a 
consequence, physicians in these counties may be more experienced and familiar with 
these approaches. On the other hand, under use of adjuncts, particularly prone 
positioning, might be a result of ineffective knowledge translation and perhaps, a 
resistance to change by clinicians, as has been shown to be the case for other 
interventions such as low tidal volume ventilation 17. In any case, these findings support 
prior studies 1,2, providing evidence that adjunctive strategy usage may depend more on 
clinician or health system factors than patient need. Further studies are needed to 
further dissect these important issues. 
 
Study Limitations: This study has a number of strengths. This study population is 
derived from the largest cohort of patients with ARDS in the era of the Berlin definition 
of ARDS. To our knowledge, this is the first global patient cohort study that has 
addressed the issue of adjunct use. Our study also has a number of limitations. First, 
given the prospective cohort design, all inferences are associative, and causality cannot 
be inferred. Second, we lacked the available data to determine the sequence of adjunct 
use on patients that received more than 1 adjunct. Third, we did not have access to the 
source data for the patients in the enrolling ICUs, and it is possible that not all patients 
with ARDS in participating centres were enrolled. However, enrolment of patients with 
ARDS from participating ICUs met expectations based on their recorded 2013 admission 
rates, while data from lower recruiting ICUs was not different from that from higher 
enrolling ICUs, suggesting the absence of reporting biases. We instituted a robust data 
quality control program in which all centres were requested to verify data that appeared 
inconsistent or erroneous. Fourth, the LUNG SAFE study was performed in 2014, and 
focused on adjuncts in clinical use at that time. Data reported by Duan et al in 2017 16 
and the recently published ROSE trial 18, suggest little change in the use of adjuncts such 
as prone positioning since then. However, extra-corporeal CO2 removal, a niche 
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technique in 2014, may have significantly increased in use since then as a result of 
advances in device technology 19.  
 
Conclusions: One-third of all patients with moderate-severe ARDS, while less than one 
third of non-survivors, received adjunctive strategies over the first 48 hours of ARDS. 
Patients that received adjuncts were more likely to have their ARDS recognized, be 
younger and sicker, have pneumonia, and be more difficult to ventilate than those that 
did not receive adjuncts. They were more likely to receive treatment in a European high 
income country. Clinician and system based factors such as ARDS recognition, the 
availability of particular adjunctive therapies, and the local expertise available may be 
more important factors than patient requirement or cost in driving the frequency and 
type of adjunct used. A more consistent and evidence driven approach to the use of 
adjuncts may reduce costs and improve outcomes in patients with moderate-severe 
ARDS.  
Author Contributions: AD, ER, TP, GB, and JGL conceived the study. ER and TP 
performed analyses for the study. AD, ER and JGL wrote the first draft of the 
manuscript. All authors provided critical input into manuscript drafting, and revisions. 
JGL is the guarantor of the paper. 
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Figure Legends 
 
 
Figure 1: Study population regarding the use of adjunctive strategies in all patients with 
moderate-severe Acute Respiratory Distress Syndrome (PaO2/FiO2<150) who required 
invasive ventilation over the first 48 hours 
 
Figure 2:  Pattern of adjunctive therapy use over the first 48h of ARDS stratified by 
hospital survival.  
Abbreviations. NMBA: neuro muscular blocking agents; ECMO: extracorporeal 
membrane oxygenation; VD: vasodilators; HFOV: high frequency oscillatory ventilation. 
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Table 1: Demographics, illness severity and ventilatory management data for patients with 
moderate-severe ARDS (i.e. PaO2/FiO2<150 in the first 48 hours of ARDS onset (n=1146)). 
 
 Conventional 
Therapy  
Any Adjunct ≥ 1 widely available 
Adjunct  
≥ 1 Specialized 
Adjunct  
Number of Patients, (%) 
[95% CI] 
811 (71%) 
[68-73%] 
335 (29%) 
[27-32%] 
249 (22%) 
[19-24%] 
86 (8%) 
[6-9%] 
Age, years, median (IQR) 64 (51-73) 59 (46-72)* 58 (45-72)* 62 (48-71) 
Female 295 (36.4) 126 (37.6) 92 (36.9) 34 (39.5) 
BMI, median (IQR) 26.0 (22.8-30.2) 26.8 (23.4-30.9)* 27.1 (23.4-30.9) 26.2 (23.5-30.9) 
Clinical recognition of 
ARDS at baseline 
265 (32.7) 152 (45.4)* 119 (47.8)* 33 (38.4) 
ARDS less than 24 h 104 (12.8) 37 (11.0) 28 (11.2) 9 (10.5) 
Illness severity (worst during 48h) 
Adjusted SOFA  11 (8.4-14) 12 (9.6-15)* 12 (10-15.6)* 12 (9.6-14.4) 
Adjusted Non-Pulmonary 
SOFA 
7.5 (5-10) 8.9 (6-11.3)* 9 (6-11.3)* 8.8 (6.3-11) 
pH 7.31 (7.22-7.39) 7.26 (7.17-7.34)* 7.25 (7.16-7.33)* 7.27 (7.19-7.38)† 
PaO2/FiO2  105 (80-129) 89 (68-114)* 89 (69-112)* 93 (66-118)* 
FiO2, median (IQR) 0.5 (0.4-0.7) 0.6 (0.5-0.8)* 0.6 (0.5-0.8)* 0.6 (0.5-0.8)* 
Ventilator Settings (worst during 48h) 
PaCO2 46 (40-58) 52 (44-61)* 53 (45-62)* 47 (41-59) 
Tidal volume (ml/ kg 
predicted body weight ) 
8.0 (7.0-9.3) 7.3 (6.5-8.6)* 7.4 (6.5-8.5)* 7.3 (6.5-9.2)* 
PEEP  10 (7-10) 10 (8-14)* 12 (8-14)* 10 (10-13)* 
Peak Inspiratory Pressure  28 (24-33) 32 (28-38)* 33 (28-38)* 31 (26-37)*† 
Plateau Pressure 23 (19-28) 27 (24-30)* 27 (24-30)* 25 (20-29) 
Total respiratory rate 22 (18-27) 25 (20-30)* 26 (20-30)* 24 (20-29) 
ICU variables 
Number of beds 2.6 (1.5-4.5) 2.3 (1.5-3.8) 2.5 (1.6-4.0) 2.0 (1.4-3.1) 
Physicians per bed, 
median (IQR) 
0.21 (0.10-0.35) 0.25 (0.12-0.42)* 0.27 (0.12-0.42) 0.25 (0.11-0.44) 
Nurses per bed, median 
(IQR) 
0.76 (0.5-1.0) 0.58 (0.42-0.90)* 0.50 (0.42-0.75)* 0.83 (0.50-1.04) 
Academic 607 (76.8) 239 (74.2) 175 (73.5) 64 (76.2) 
 
* Any adjunct statistically different than Conventional therapy 
† Value statistically different from those observed in the widely available adjunct therapy 
Note: In patients in whom both widely available and specialized adjuncts were used, the 
patient was classified based on the use of the specialized adjunct. 
Ventilator settings – data available: 
Worst parameter during 48h: Adjusted SOFA (n=1146); Adjusted non respiratory SOFA 
(n=1144); pH (n=1135); PaO2/FiO2 (n=1146); paCO2 (n=1135); Tidal volume/predicted body 
weight (n=1095); PEEP (n=1146); Peak inspiratory pressure (n=1116); Plateau pressure 
(n=575); Total respiratory rate total (n=1146). 
 
 Table 2: Patterns of adjunctive measures use in the first 48 h of patients with moderate-
severe ARDS (n=1146) stratified by ICU survival. 
Abbreviations. ARDS: Acute Respiratory Distress Syndrome; NMBA: neuro muscular blocking agents; 
HFOV: high frequency oscillatory ventilation; ECMO: Extracorporeal Membrane Oxygenation 
 
 
 
 
 
 
Patients 
receiving 
measure 
n (%) [95%CI] 
Concomitant 
NMBA 
n (%) [95%CI] 
Concomitant 
Prone 
Position 
n (%) [95%CI] 
Concomitant 
ECMO 
n (%) [95%CI] 
Concomitant 
Inhaled 
Vasodilator  
n (%) [95%CI] 
Concomitant 
HFOV 
n (%) [95%CI] 
No other 
Adjuncts 
n (%) [95%CI] 
NMBA  
All patients, n=1146 
 
 
ARDS non-survivors, n=458 
 
255 (22.3) 
[19.9-24.8] 
 
116 (25.3) 
[21.4-29.6] 
 
 
 
57/255 (22.4) 
[17.4-28.0] 
 
23/116 (19.8) 
[13.0-28.3] 
 
4/255 (1.6) 
[0.4-4.0] 
 
2/116 (1.7) 
[0.2-6.1] 
 
21/255 (8.2) 
[5.2-12.3] 
 
6/116 (5.2) 
[1.9-10.9] 
 
3/255 (1.2) 
[0.2-3.4] 
 
2/116 (1.7) 
[0.2-6.1] 
 
177/255 (69.4) 
[63.3-75.0] 
 
86/116 (74.1) 
[65.2-81.8] 
Prone position 
All patients, n=1146 
 
 
ARDS non-survivors, n=458 
 
79/1146(6.9) 
[5.5-8.5] 
 
31/458 (6.8) 
[4.6-9.5] 
 
57/79 (72.2) 
[60.9-81.7] 
 
23/31 (74.2) 
[55.4-88.1] 
 
  
1/79 (1.3) 
[0.0-6.8] 
 
0/31 (0) 
[0-11.2] 
 
 
6/79 (7.6) 
[2.8-15.8] 
 
2/31 (6.5) 
[0.8-21.4] 
 
 
0/79 (0) 
[0-4.6] 
 
0/31 (0) 
[0-11.2] 
 
 
20/79 (25.3) 
[16.2-36.4] 
 
7/31 (22.6) 
[9.6-41.1] 
 
ECMO 
All patients, n=1146 
 
 
ARDS non-survivors, n=458 
 
11/1146 (1.0) 
[0.5-1.7] 
 
6/458 (1.3) 
[0.5-2.8] 
 
4/11 (36.4) 
[10.9-69.2] 
 
2/6 (33.3) 
[4.3-77.7) 
 
 
1/11 (9.1) 
[0.2-41.3] 
 
0/6 (0) 
[0-45.9] 
 
 
 
 
3/11 (27.3) 
[6.0-61.0] 
 
3/6 (50.0) 
[11.8-88.2] 
 
 
0/11 (0) 
[0-28.5] 
 
0/6 (0) 
[0-45.9] 
 
 
5/11 (45.5) 
[16.7-76.6] 
 
2/6 (33.3) 
[4.3-77.7] 
 
Inhaled vasodilators  
All patients, n=1146 
 
 
ARDS non-survivors, n=458 
 
74/1146 (6.5) 
[5.1-8.0] 
 
30/458 (6.6) 
[4.4-9.2] 
 
21/74 (28.4) 
[18.5-40.1] 
 
6/30 (20.0) 
[7.7-38.6] 
 
 
6/74 (8.1) 
[3.0-16.8] 
 
2/30 (6.7) 
[0.8-22.1] 
 
 
3/74 (4.1) 
[0.8-11.4] 
 
3/30 (10.0) 
[2.1-26.5] 
 
 
 
2/74 (2.7) 
[0.3-9.4] 
 
2/30 (6.7) 
[0.8-22.1] 
 
 
48/74 (64.9) 
[52.9-75.6] 
 
20/30 (66.7) 
[47.2-82.7] 
 
HFOV 
All patients, n=1146 
 
 
ARDS non-survivors, n=458 
 
6/1146 (0.5) 
[0.2-1.1] 
 
4/458 (0.9) 
[0.2-2.2] 
 
3/6 (50.0) 
[11.8-88.2] 
 
2/4 (50.0) 
[6.8-93.2] 
 
 
0/6 (0) 
[0-45.9] 
 
0/4 (0) 
[0-60.2] 
 
 
0/6 (0) 
[0-45.9] 
 
0/4 (0) 
[0-60.2] 
 
 
2/6 (33.3) 
[4.3-77.7] 
 
2/4 (50.0) 
[6.8-93.2] 
 
 
 
 
2/6 (33) 
[4.3-77.7] 
 
1/4 (25.0) 
[0.6-80.6] 
 
None of the Above 
All patients, n=1146 
 
 
ARDS non-survivors, n=458 
 
811/1146 (70.8) 
[68.0-73.4] 
 
308/458 (67.2) 
[62.7-71.5] 
      
Table 3: Geo-economic distribution of adjunctive measures use in the first 48 h of patients 
with moderate-severe ARDS (n=1146). 
Adjunctive therapy 
within 48h of ARDS 
All 
patients 
(n=1146) 
High income 
Europe 
(n=638) 
High income 
Non-European 
(n=269) 
Middle 
income 
Countries 
(n=239) 
P-value 
(between 
groups) 
Adjunct Use 
   Any, n (%) [95% CI] 
    
 
   None, n (%) [95% CI] 
 
 
335 (29.2) 
[26.6-32.0] 
 
811 (70.8) 
[68.0-73.4] 
 
230 (36.1) 
[32.3-39.9] 
 
408 (63.9) 
[60.1-67.7] 
 
64 (23.8) 
[18.8-29.3]* 
 
205 (76.2) 
[70.7-81.2]* 
 
41 (17.2) 
[12.6-22.5]* 
 
198 (82.8) 
[77.5-87.4]* 
<0.001 
 
 
Neuromuscular blockade n (%) 
[95% CI] 
255 (22.3) 
[19.9-24.8] 
183 (28.7) 
[25.2-32.4] 
48 (17.8) 
[13.5-23.0]* 
24 (10.0) 
[6.5-14.6]*† 
<0.001 
Prone Positioning, n (%) [95% CI] 
79 (6.9) 
[5.5-8.5] 
67 (10.5) 
[8.2-13.1] 
2 (0.7) 
[0.1-2.7]* 
10 (4.2) 
[2.0-7.6]*† 
<0.001 
ECMO, n (%) [95% CI] 
11 (1.0) 
[0.5-1.7] 
7 (1.1) 
[0.4-2.2] 
4 (1.5) 
[0.4-3.8] 
0 (0) 
[0-1.5] 
0.200 
Inhaled vasodilators, n (%) [95% 
CI] 
74 (6.5) 
[5.1-8.0] 
43 (6.7) 
[4.9-9.0] 
18 (6.7) 
[4.0-10.4] 
13 (5.4) 
[2.9-9.1] 
0.772 
High Frequency Oscillation, n (%) 
[95% CI] 
6 (0.5) 
[0.2-1.1] 
2 (0.3) 
[0.0-1.1] 
4 (1.5) 
[0.4-3.8] 
0 (0) 
[0-1.5] 
0.052 
 
* Value statistically different from those observed in European countries with high income. 
† Value sta3s3cally different from those observed in non-European countries with high income.  
Abbreviations. ARDS: Acute Respiratory Distress Syndrome, ECMO: Extracorporeal 
Membrane Oxygenation 
 
 
 
Table 4. Multivariate logistic regression analysis of factors associated with the use of any 
adjunct strategies in patients with moderate-severe ARDS within the first 48 hours. 
 
Variable OR 95% CI p 
Age 0.98 0.98-0.99 0.003 
BMI 1.02 1.00-1.05 0.034 
Pneumonia (Ref: No) 1.45 1.03-2.02 0.031 
Inhalation (Ref: No) 3.32 1.08-10.18 0.036 
Adjusted non respiratory SOFA 1.07 1.03-1.12 0.001 
PaO2/FiO2 Ratio 0.99 0.99-1.00 0.021 
Tidal Volume (ml/kg PBW) 0.80 0.73-0.88 <0.001 
PIP 1.03 1.01-1.05 0.007 
PEEP 1.13 1.08-1.19 <0.001 
Nurses per bed 0.56 0.38-0.82 0.003 
Physicians per bed 2.42 1.33-4.40 0.004 
Clinician recognition at baseline 1.53 1.10-2.12 0.012 
High income RW (Ref: High 
income Europe) 
0.62 0.40-0.96 0.033 
Middle income countries (Ref: 
High income Europe) 
0.24 0.14-0.39 <0.001 
Sample size n=956 
 
 


